This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Sesen Bio Dividend

Dividend criteria checks 0/6

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield2.9%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Earnings per share-US$0.098
Dividend yield forecast in 3Yn/a

Recent dividend updates

Recent updates

Sesen Bio and Carisma Therapeutics announce merger agreement

Sep 21

Sesen Bio GAAP EPS of -$0.16 misses by $0.03

Aug 08

Sesen Bio granted additional time period for regaining compliance

Jul 27

Sesen Bio slips after decision to pause U.S. studies for lead asset

Jul 18

Sesen Bio: Another Net-Net Biopharma Exploring Strategic Alternatives

Jun 02

We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth Carefully

Apr 17
We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn Rate

Dec 05
We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn Rate

Sesen Bio: Interesting Price Drop After CRL

Nov 24

Sesen Bio: Hoping For An Easy Revalidation Of Vicineum By 2022

Nov 17

Sesen Bio: The Road Ahead

Aug 23

Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00

Aug 12
Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00

Sesen Bio: Binary Event Approaching

Jun 13

Sesen Bio inks global supply partnership with Qilu Pharmaceutical

Jun 02

Sesen Bio EPS misses by $0.27

May 10

Sesen Bio: Long-Term And Short-Term Potential In Advance Of Its First PDUFA

May 07

News Flash: 3 Analysts Think Sesen Bio, Inc. (NASDAQ:SESN) Earnings Are Under Threat

Feb 18
News Flash: 3 Analysts Think Sesen Bio, Inc. (NASDAQ:SESN) Earnings Are Under Threat

Sesen announces positive FDA meeting for vicineum's marketing application

Feb 01

Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?

Jan 26
Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?

Sesen Bio/Qilu Pharma's Vicineum IND application accepted for review in China

Jan 13

Sesen Bio files US application for its Vicineum in bladder cancer

Dec 21

Sesen Bio, Inc.'s (NASDAQ:SESN) Profit Outlook

Dec 21
Sesen Bio, Inc.'s (NASDAQ:SESN) Profit Outlook

Sesen Bio: A Look At Vicineum's Potential

Nov 29

Sesen Bio, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 09

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if SESN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SESN's dividend payments have been increasing.


Dividend Yield vs Market

Sesen Bio Dividend Yield vs Market
How does SESN dividend yield compare to the market?
SegmentDividend Yield
Company (SESN)n/a
Market Bottom 25% (US)1.6%
Market Top 25% (US)4.8%
Industry Average (Biotechs)2.9%
Analyst forecast in 3 Years (SESN)n/a

Notable Dividend: Unable to evaluate SESN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SESN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as SESN has not reported any payouts.


Discover strong dividend paying companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.